XTL Biopharmaceuticals Ltd. reported its financial results for the nine months ending September 30, 2024, showing a revenue increase to $162,000, driven by its acquisition of The Social Proxy; however, total loss was approximately $772,000. The company also noted ongoing regional conflicts could impact operations, but currently sees no significant adverse effects.